Surfactant for a Patient with Refractory Pyopneumothorax and Acute Respiratory Distress Syndrome Due to Pneumococcal Necrotizing Pneumonia Complicated by a Bronchopleural Fistula

Pediatr Allergy Immunol Pulmonol. 2022 Sep;35(3):120-123. doi: 10.1089/ped.2022.0112.

Abstract

Background: Necrotizing pneumonia rarely occurs in children, but when it does it can be complicated by bronchopleural fistula, empyema, pneumothorax, sepsis, and acute respiratory distress syndrome (ARDS). Antimicrobial therapy is the cornerstone of its management; however, surgery is necessary in some cases. Ideally, surgical interventions are kept to a minimum, but this is not always possible if there is a mass effect from air and fluid in the pleural space, pulmonary necrosis leading to massive hemoptysis, uncontrolled sepsis, or difficulties with assisted ventilation. Case Presentation: Herein we present a patient with refractory pyopneumothorax and ARDS due to pneumococcal necrotizing pneumonia complicated by a bronchopleural fistula. The patient's clinical condition deteriorated despite antibiotics, surgical drainage, and assisted ventilation. Owing to pneumothorax with a high percentage of air leakage, bilateral diffuse collapse of the lungs, and insufficient oxygenation, surgical treatment was considered, but because of the patient's lack of tolerance for surgery due to hemodynamic reasons and the complications associated with surgery, medical treatment was determined to be more appropriate. Surfactant treatment was administered to the patient, resulting in significant clinical improvement. Conclusion: To the best of our knowledge, this is the first report of the use of surfactant to treat ARDS due to necrotizing pneumonia. Based on the presented case, we think surfactant can be considered as a salvage treatment for such patients.

Keywords: acute respiratory distress syndrome; bronchopleural fistula; necrotizing pneumonia; pneumothorax; surfactant.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bronchial Fistula* / complications
  • Bronchial Fistula* / surgery
  • Child
  • Empyema, Pleural* / complications
  • Empyema, Pleural* / drug therapy
  • Humans
  • Pleural Diseases* / complications
  • Pleural Diseases* / drug therapy
  • Pneumonia, Necrotizing* / complications
  • Pneumonia, Necrotizing* / drug therapy
  • Pneumonia, Pneumococcal* / complications
  • Pneumonia, Pneumococcal* / diagnosis
  • Pneumonia, Pneumococcal* / drug therapy
  • Pneumothorax* / complications
  • Pneumothorax* / drug therapy
  • Respiratory Distress Syndrome* / complications
  • Respiratory Distress Syndrome* / drug therapy
  • Sepsis* / complications
  • Sepsis* / drug therapy
  • Streptococcus pneumoniae
  • Surface-Active Agents

Substances

  • Anti-Bacterial Agents
  • Surface-Active Agents